Table 4 Sub-group analysis for patients without a history of HCC before DAA therapy

Male

163

(64.4)

5

(62.5)

1

Age, year

58.0

± 12.8

67.3

± 7.6

0.044

BMI, kg/m²

23.7

± 4.0

23.1

± 2.7

0.806

HCV genotype

0.785

 1a

12

(4.7)

0

 1b

121

(47.8)

6

(75)

 2

5

(2.0)

0

 3

20

(7.9)

0

 6

93

(36.8)

2

(25)

HCV viral load before DAA therapy, ×10⁶ IU/ml

3.6

± 9.5

3.7

± 2.6

0.154

DAA therapy duration, weeks

12 [8, 12]

12 [12, 12]

0.154

Haemoglobin, g/dL

13.8

± 2.0

14.6

± 2.3

0.092

Platelets, ×10⁹/L

177.0

± 71.4

134.3

± 51.2

0.337

Creatinine, umol/L

85.3

± 88.4

78.3

± 33.1

0.039

ALT at the start of DAA therapy, IU/L

84.8

± 112.3

115.4

± 97.7

0.415

ALT at the end of DAA therapy, IU/L

23.7

± 18.3

40.3

± 46.0

0.155

Total bilirubin, umol/L

12.8

± 6.5

14.9

± 5.7

0.159

Albumin, g/L

38.2

± 5.0

39.3

± 3.5

0.216

INR

1.06

± 0.08

1.01

± 0.04

0.492

Prothrombin time, second

11.6

± 1.1

11.1

± 0.6

0.059

AFP at the start of DAA therapy, ng/ml

8.3

± 17.0

64.3

± 92.8

0.001

AFP at the end of DAA therapy, ng/ml

4.0

± 5.1

6.8

± 1.8

0.002

HBV co-infection

15

(5.9)

1

(12.5)

0.401

HIV co-infection

20

(7.9)

0

1

Diabetes mellitus

46

(18.2)

2

(25)

0.642

Cirrhosis

109

(43.1)

6

(75)

0.144

Liver stiffness, kPa

9.9 [7, 14.2]

22.3 [14.4, 26.6]

0.009

Fatty liver

98

(38.7)

2

(25)

0.714

SVR 12

250

(98.8)

8

(100)

1

Evidence of portal hypertension

50

(19.8)

4

(50)

0.06

History of anti-viral treatment before DAA therapy

65

(25.7)

4

(50)

0.214

HCV infection suspected to be via previous intra-venous drug abuse

109

(43.1)

4

(50)

0.730

HCV infection suspected to be via previous blood transfusion

56

(22.1)

3

(37.5)

0.386